RetiSpec

Noninvasive Eye Scan to Detect Alzheimer's Disease

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
RetiSpec
03/07/2021
Cognitive Assessment & Enhancement
Medical devices | Medical equipment
Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis)
Other imaging methods
01/01/2016
"1-10"

RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer's disease biomarkers in the eye. The company's goal is to enable the widespread early detection of Alzheimer's disease through accessible and scalable screening.



Through a quick eye exam, RetiSpec opens a window of opportunity for timely and specific therapeutic interventions so that the progression of the disease can be slowed or even prevented.



The company's patented technology harnesses hyperspectral imagery in synergy with machine learning to allow for rapid, simple, and cost-effective identification of Alzheimer's biomarkers years before the emergence of clinical symptoms. RetiSpec uses computer vision and machine-learning algorithms to detect the unique signatures of Alzheimer's biomarkers in seconds.